Interaction of BAG-1 with retinoic acid receptor and its inhibition of retinoic acid-induced apoptosis in cancer cells

被引:106
作者
Liu, R [1 ]
Takayama, S [1 ]
Zheng, Y [1 ]
Froesch, B [1 ]
Chen, GQ [1 ]
Zhang, X [1 ]
Reed, JC [1 ]
Zhang, XK [1 ]
机构
[1] Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA
关键词
D O I
10.1074/jbc.273.27.16985
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BAG-1 (also known as RAP46) is an anti-apoptotic protein, which has been shown previously to interact with a number of nuclear hormone receptors, including receptors for glucocorticoid, estrogen, and thyroid hormone. We show here that BAG-I also interacts with retinoic acid receptor (RAR). Gel retardation assays demonstrated that in vitro translated BAG-1 protein could effectively inhibit the binding of RAR but not retinoid X receptor (RXR) to a number of retinoic acid (RA) response elements (RAREs), A glutathione S-transferase-BAG-1 fusion protein also specifically bound RAR but not RXR. Interaction of BAG-I and RAR could also be demonstrated by yeast two-hybrid assays. In transient transfection assays, co-transfection of BAG-1 expression plasmid inhibited the transactivation activity of RAR/RXR heterodimers but not RXR/RXR homodimers. When stably expressed in breast cancer cell lines, BAG-1 inhibited binding of RAR/RXR heterodimer to a number of RAREs and suppressed RA-induced growth inhibition and apoptosis. In addition, RA-induced suppression of Bcl-2 expression was abrogated by overexpression of BAG-1. These results demonstrate that BAG-1 can regulate retinoid activities through its interaction with RAR and suggest that elevated levels of BAG-I protein could potentially contribute to retinoid resistance in cancer cells.
引用
收藏
页码:16985 / 16992
页数:8
相关论文
共 53 条
[21]   Nuclear receptor coactivators and corepressors [J].
Horwitz, KB ;
Jackson, TA ;
Rain, DL ;
Richer, JK ;
Takimoto, GS ;
Tung, L .
MOLECULAR ENDOCRINOLOGY, 1996, 10 (10) :1167-1177
[22]   A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors [J].
Kamei, Y ;
Xu, L ;
Heinzel, T ;
Torchia, J ;
Kurokawa, R ;
Gloss, B ;
Lin, SC ;
Heyman, RA ;
Rose, DW ;
Glass, CK ;
Rosenfeld, MG .
CELL, 1996, 85 (03) :403-414
[23]   NONSTEROID NUCLEAR RECEPTORS - WHAT ARE GENETIC-STUDIES TELLING US ABOUT THEIR ROLE IN REAL-LIFE [J].
KASTNER, P ;
MARK, M ;
CHAMBON, P .
CELL, 1995, 83 (06) :859-869
[24]  
KOCHHAR DM, 1993, PROG CLIN BIOL RES, V383, P815
[25]   THE N-TERMINAL PART OF TIF1, A PUTATIVE MEDIATOR OF THE LIGAND-DEPENDENT ACTIVATION FUNCTION (AF-2) OF NUCLEAR RECEPTORS, IS FUSED TO B-RAF IN THE ONCOGENIC PROTEIN T18 [J].
LEDOUARIN, B ;
ZECHEL, C ;
GARNIER, JM ;
LUTZ, Y ;
TORA, L ;
PIERRAT, B ;
HEERY, D ;
GRONEMEYER, H ;
CHAMBON, P ;
LOSSON, R .
EMBO JOURNAL, 1995, 14 (09) :2020-2033
[26]   INTERACTION OF THYROID-HORMONE RECEPTOR WITH A CONSERVED TRANSCRIPTIONAL MEDIATOR [J].
LEE, JW ;
RYAN, F ;
SWAFFIELD, JC ;
JOHNSTON, SA ;
MOORE, DD .
NATURE, 1995, 374 (6517) :91-94
[27]  
Li Y, 1998, INT J CANCER, V75, P88, DOI 10.1002/(SICI)1097-0215(19980105)75:1<88::AID-IJC14>3.0.CO
[28]  
2-9
[29]  
Liu Y, 1996, MOL CELL BIOL, V16, P1138
[30]   THE RXR HETERODIMERS AND ORPHAN RECEPTORS [J].
MANGELSDORF, DJ ;
EVANS, RM .
CELL, 1995, 83 (06) :841-850